Itopride hydrochloride

Quick links

Choose a section

Quick links to important sections

Advertisements

Itopride hydrochloride

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Itopride hydrochloride

What is Itopride hydrochloride?

Itopride hydrochloride is an oral medication categorized as a prokinetic agent. It is primarily used to manage gastrointestinal symptoms associated with functional dyspepsia and other conditions involving impaired gastric motility.

Mechanism of Action

Itopride hydrochloride works through a dual mechanism to enhance gastrointestinal movement:

  • Dopamine D2 Receptor Antagonism: By blocking these receptors, it helps increase the release of acetylcholine, a neurotransmitter responsible for muscle contractions in the digestive tract.
  • Acetylcholinesterase Inhibition: It inhibits the enzyme that breaks down acetylcholine, allowing the neurotransmitter to remain active for a longer duration.

These combined actions increase the tone and motility of the upper gastrointestinal tract, specifically facilitating gastric emptying and improving the coordination between the stomach and the duodenum.

Clinical Applications

The medication is typically utilized to alleviate physical discomforts arising from slow digestion. Common symptoms addressed include:

  • Postprandial fullness (a feeling of excessive fullness after eating)
  • Upper abdominal pain or discomfort
  • Early satiety (feeling full shortly after starting a meal)
  • Bloating and nausea
  • Heartburn

Unlike some earlier prokinetic agents, itopride hydrochloride is known for its high degree of specificity for the gastrointestinal tract, which influences its overall metabolic profile and its interaction with various physiological systems.

Advertisements

What side effects are possible with Itopride hydrochloride?

Possible Side Effects and Safety Information

Itopride hydrochloride is associated with a range of possible adverse effects, categorized by the system-organ classes they affect. Regulatory documents classify the incidence of these effects, which include those seen during clinical trials and those reported post-marketing.

Common and Uncommon Adverse Reactions

The most frequently reported adverse reactions, classified as Common, include gastrointestinal effects such as diarrhea and abdominal pain, and central nervous system effects such as headache and dizziness. Uncommon reactions include changes in blood counts, specifically leucopenia, and hormonal changes like hyperprolactinaemia.

System-Organ Class Common Adverse Reactions (Examples) Uncommon Adverse Reactions (Examples)
Gastrointestinal Disorders Diarrhea, Abdominal pain Salivary hypersecretion
Nervous System Disorders Headache, Dizziness —
Blood & Lymphatic System — Leucopenia
Endocrine Disorders — Hyperprolactinaemia

Serious and Clinically Significant Risks

Post-marketing surveillance has identified serious adverse reactions with an unknown frequency. These include anaphylactoid reactions and signs of liver dysfunction, such as jaundice (yellowing of the skin and eyes) and elevated liver enzyme levels. The drug's mechanism of action can potentiate cholinergic effects, requiring caution to prevent related side effects.

Contraindications and Safety Considerations

Itopride is contraindicated in patients with a known hypersensitivity to the drug. It must also not be used in conditions where increasing gastrointestinal motility could be harmful, such as in cases of gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Special caution is advised for elderly patients due to the higher probability of reduced hepatic or renal function, which can affect drug clearance. Safety has not been established in pediatric patients under 16 years of age. Due to excretion into milk in animal studies, breastfeeding should be avoided if treatment is necessary, and use during pregnancy is advised only when the therapeutic benefit clearly outweighs the potential risk.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory prescribing information for Itopride hydrochloride confirms that no specific cases of overdose in humans have been formally reported or documented in clinical practice. Consequently, the official guidance on managing an overdose is based on standardized emergency procedures and supportive care, rather than specific, confirmed symptom clusters.

Required Emergency Response

It is mandatory to consult a doctor or seek immediate medical attention following the ingestion of an excessive amount of tablets or in the event of accidental ingestion. This requirement applies to all instances of overexposure. The labeling specifically notes that accidental ingestion by children also necessitates immediate professional consultation.

Official Management Measures

The documented procedural steps for overdose management are listed as the standard usual measures to be applied by a healthcare professional. These include:

  • Application of gastric lavage
  • Administration of symptomatic therapy

The official documentation further specifies that no specific antidote is known to counteract the effects of Itopride hydrochloride overdose. Therefore, all care must be supportive, focusing on maintaining vital functions under medical supervision.

Advertisements

Therapeutic Uses of Itopride hydrochloride

Main Uses of Itopride Hydrochloride

Itopride hydrochloride is a gastroprokinetic agent primarily used to manage symptoms associated with functional gastrointestinal disorders. Its primary function is to enhance gastrointestinal motility, which helps facilitate the movement of food through the digestive tract.

Functional Dyspepsia

The most common application of itopride hydrochloride is in the treatment of functional dyspepsia. This condition involves chronic or recurrent discomfort in the upper abdomen without an identifiable structural cause. It helps alleviate several specific symptoms, including:

  • Postprandial fullness: A sensation that food remains in the stomach for an abnormally long time after eating.
  • Early satiety: Feeling full shortly after beginning a meal, preventing the consumption of a normal-sized portion.
  • Upper abdominal pain or discomfort: General aching or pressure in the stomach area.
  • Bloating: A feeling of tightness or swelling in the upper abdomen.

Gastrointestinal Motility Support

Beyond dyspepsia, itopride hydrochloride is utilized to address general motility issues where the stomach does not empty at a normal rate. By increasing the frequency and force of contractions in the stomach and upper intestines, it helps reduce the transit time of ingested material.

Benefits of Treatment

Improved Digestive Comfort

By accelerating gastric emptying, itopride hydrochloride reduces the duration of discomfort associated with slow digestion. This often leads to a significant reduction in the physical heaviness and pressure experienced by individuals with motility disorders.

Symptom Relief and Daily Function

The primary benefit of this medication is the stabilization of digestive processes. Effective management of symptoms like nausea, heartburn, and bloating can improve an individual's ability to maintain regular dietary habits and enhance overall comfort during and after meals.

Mechanism of Action Support

Itopride hydrochloride provides a dual-action approach to digestive health. It works by inhibiting acetylcholinesterase, which increases the levels of acetylcholine available to stimulate muscle contractions. Simultaneously, it acts as a dopamine D2 receptor antagonist, further promoting the release of acetylcholine and preventing the inhibitory effects of dopamine on the digestive tract muscles.

Regulatory References

  1. NIH MedlinePlus guidance on similar treatments
Advertisements

Eligibility and Restrictions for Use

Itopride hydrochloride is intended for use in adults and has specific eligibility rules based on regulatory standards. Use is strictly contraindicated in patients with known hypersensitivity to the medicine or in whom increased gastrointestinal motility could be detrimental, such as those with gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Population Group Eligibility Status (Official Labeling)
Pediatric Patients (Under 16) Not established (Safety and efficacy data is insufficient).
Elderly Patients (65+) Requires appropriate caution and close monitoring due to potential for decreased organ function.
Hepatic or Renal Impairment Requires careful monitoring; dose reduction or therapy termination may be required for adverse reactions.
Pregnancy Conditional Use (Only if therapeutic benefits significantly outweigh possible risks).
Lactation (Breastfeeding) Not Recommended (A decision must be made to discontinue breastfeeding or discontinue therapy).

This medicine is also contraindicated for individuals with rare hereditary disorders such as galactose intolerance or total lactase deficiency due to the presence of lactose excipients. The regulatory profile is built to exclude populations where increasing gut movement poses a direct risk, or where clinical data is insufficient.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Itopride hydrochloride is defined by its influence on gastrointestinal motility and its unique metabolic pathway, as documented in regulatory prescribing information.


Pharmacokinetic Interactions and Administration Constraints

Itopride hydrochloride's gastrokinetic action accelerates gastric emptying, which may, in turn, influence the absorption of other orally co-administered medicines. Particular caution is specified in the regulatory label for oral drugs with a narrow therapeutic index, or those formulated as sustained-release or enteric-coated products, as their systemic exposure is highly susceptible to change by altered gastrointestinal transit time. The official documentation also notes that anti-ulcer drugs, such as Cimetidine and Ranitidine, do not affect the prokinetic action of Itopride.

Metabolic and Pharmacodynamic Interactions

Regarding metabolism, interactions mediated by the Cytochrome P450 (CYP) enzyme system are not expected. This is because Itopride is primarily metabolized by the Flavine Monooxygenase (FMO) system. This metabolic pathway minimizes the risk of significant pharmacokinetic interactions arising from common CYP inhibitors or inducers. However, a clear pharmacodynamic antagonism is documented with anticholinergic agents. Co-administration with these substances, such as atropine or related compounds, may reduce or counteract the prokinetic efficacy of Itopride hydrochloride.

Population-Specific Interaction Notes

Official documents advise that adequate caution must be exercised when Itopride is administered to elderly patients. This constraint recognizes the greater frequency of reduced hepatic and renal function in this population, which may impair the drug's clearance and increase the potential for interaction risk or severity.

Advertisements

Mechanism of Action

Itopride hydrochloride acts through two distinct mechanistic domains to modulate the signaling pathways that regulate the contractility of upper gastrointestinal (GI) smooth muscle. It primarily engages targets within the enteric nervous system.


Dopamine D2 Receptor Antagonism

Itopride acts as an antagonist on the Dopamine D2 receptors located in the myenteric plexus (a nerve network in the GI wall). Dopamine typically acts as an inhibitory neurotransmitter, reducing the release of the signaling molecule acetylcholine (ACh) from cholinergic neurons. By blocking the D2 receptors, Itopride eliminates the inhibitory dopaminergic signal. The mechanism eliminates the inhibitory effect, resulting in enhanced acetylcholine release and increased nerve-mediated signal transmission within the GI wall.


Acetylcholinesterase Enzyme Inhibition

The drug also engages a mechanism that inhibits the enzyme acetylcholinesterase (AChE). This enzyme catalyzes the hydrolysis of acetylcholine (ACh) in the synaptic clefts of the myenteric plexus. By inhibiting AChE, Itopride prevents the metabolic degradation of the released acetylcholine. This action increases the concentration and duration of ACh activity at the post-synaptic receptors. This action enhances muscular contraction force and duration across the gastrointestinal smooth muscle.

Advertisements

Dosage and Administration Information

The use of Itopride hydrochloride follows standardized administration protocols, focusing on procedural details. The medicine is provided as an oral solid dosage form, typically a 50 mg film-coated tablet.

The Standard Dosing Regimen for adults is a total of 150 mg daily, administered as one 50 mg tablet, three times a day (TID). A defining procedural instruction is the Time-Relationship to Meals, which requires the tablet to be taken before meals (preprandially) to align with its proper use. The maximum recommended daily dose is 150 mg. Furthermore, the duration of administration is generally limited; in clinical studies, the course of treatment was maximally 8 weeks.

For proper administration, the tablets should be swallowed whole with a sufficient amount of liquid. The score line on the 50 mg tablet is present only to assist with swallowing and is not intended for dividing the unit into smaller doses. Standard procedure for a Missed Dose indicates that it should be taken as soon as possible, but if it is almost time for the next scheduled dose, the missed dose must be skipped entirely.

Population-specific procedures apply to certain patient groups. The use of Itopride hydrochloride has not been established for children under 16 years of age. For older adults and patients with reduced hepatic or renal function, careful monitoring is required, and standard protocols indicate that the dose should be reduced or therapy discontinued if necessary. These procedural rules structure the standardized use of the medicine according to regulatory specifications.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Itopride Hydrochloride

The research on Itopride hydrochloride research examined outcomes related to certain chronic digestive discomforts and physiological function. The evidence gathered so far comes mainly from formal randomized controlled trials (RCTs) and physiological studies that research examined over defined time intervals.


Evidence for Functional Dyspepsia Symptoms

Research has concentrated heavily on symptoms associated with functional dyspepsia (FD), a condition where symptoms may vary in intensity such as postprandial fullness, early satiety, and upper abdominal discomfort.

Initial research involved short-term RCTs, typically lasting between four to eight weeks, which used in research exploring how symptoms change over time. Findings describe patterns observed in the studies where certain specific individual symptoms were described in the treatment groups across several aggregated studies. However, the data show patterns related to the overall global patient assessment—the biggest measure of feeling better—were mixed across different major international trials, meaning results varied depending on the specific study population and design.


Examining the Research on Gastric Motility

Independent research was studied for its objective influence on the physical movement of the upper gut. These physiological studies research examined objective changes in the gastric emptying rate. Findings were mixed when the same objective outcomes were measured in functional dyspepsia patients in certain trials. This means that while objective measures may show patterns of change, that physiological change may not align with the subjective patient-reported outcomes describing perceived discomfort in all cases.


Long-Term Studies and Follow-Up Duration

Most large-scale, controlled clinical trials for the drug were conducted over short-term periods (four to eight weeks). To understand patterns beyond this, open-label extension studies research explored longer follow-up durations, sometimes up to six months or one year. Controlled evidence for the durability of any observed symptom changes beyond one year is still emerging, meaning long-term effects are not fully established.


Evidence in Specific Patient Populations

The existing studies research examined primarily focused on the general adult population. Data for certain groups remain insufficient from robust RCTs, including children and pregnant populations. While some older adults were observed in trials, the evidence for the very elderly remains limited, and subgroup findings are uncertain.


What is Still Uncertain About Itopride Hydrochloride Research

Overall, the research base for the primary indication is substantial, but evidence highlights what is known — and what is still uncertain. Key evidence gaps include limited follow-up durations in controlled settings and mixed findings regarding the overall global symptom response across different Phase III RCTs.

Key Studies & References

  1. Itopride in functional dyspepsia: open-label, 1-year treatment follow-up of two multicenter, randomized, double-blind, placebo-controlled trials
  2. Summary of Product Characteristics (SmPC) for Itopride hydrochloride 50 mg film-coated tablets (Used as a general regulatory reference for indication and context)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Itopride hydrochloride (FAQ)


Q: Does Itopride hydrochloride work in the central nervous system or primarily in the digestive tract?

Official product information indicates that Itopride hydrochloride is highly polar and poorly penetrates the blood-brain barrier. This means its action is primarily focused on the enteric nervous system—the complex network of nerves found in the walls of the digestive tract—rather than the central nervous system.


Q: What is the risk of neurological side effects like tremors or involuntary movements?

Tremor has been reported as a possible neurological side effect, but its exact frequency is classified as 'not known' in regulatory documents. Official warnings note that any sign of involuntary movements is a concern that regulatory information suggests discussing with a healthcare provider.


Q: What should a patient look for if they are concerned about liver problems while on this drug?

Official safety information notes that jaundice (a yellowing of the skin and eyes) has been reported, which is a visible sign of potential liver issues. It also indicates that healthcare providers may monitor liver enzyme levels during treatment, particularly for patients at higher risk.


Q: Why might some official documents mention a risk of gynecomastia?

Gynecomastia, or the enlargement of male breast tissue, has been reported as a side effect with an 'not known' frequency. Official documents suggest this may be related to hyperprolactinaemia—an uncommon condition involving elevated levels of the hormone prolactin—which the drug can potentially cause due to its mechanism.


Q: Does taking Itopride hydrochloride cause drowsiness or affect alertness when driving?

Official safety warnings state that Itopride hydrochloride may cause dizziness, which is an uncommon side effect, or generally reduce alertness. Regulatory guidance advises caution regarding driving or operating machinery if dizziness or reduced alertness occurs.


Q: What is the general frequency of serious side effects with Itopride hydrochloride?

Serious adverse reactions, which include anaphylactoid reactions and signs of liver issues like jaundice, are classified as having an 'not known' frequency in regulatory documents. This classification is often used when effects are rare and primarily reported through voluntary post-marketing surveillance rather than being quantified in clinical trials.


Q: Does official evidence indicate that Itopride hydrochloride is habit-forming?

Regulatory information and official safety documentation do not indicate that Itopride hydrochloride carries a risk of being habit-forming or of developing dependence.


Q: What is the reported interaction between grapefruit juice and Itopride hydrochloride?

Official product warnings note a potential interaction with grapefruit juice. This information is provided because components in the juice may increase the risk of adverse effects by affecting how the body processes the drug.


Q: Is Itopride hydrochloride generally suitable for use in patients with existing Parkinson's disease?

Official warnings state that Itopride hydrochloride is generally not recommended for use in patients with dopamine-related disorders, including Parkinson's disease. This caution is due to the drug's mechanism of action, which involves blocking certain dopamine receptors.


Q: How quickly does Itopride hydrochloride usually start to relieve digestive symptoms?

Official pharmacokinetic data shows that the maximum concentration of the medicine in the blood, known as Tmax, is typically reached in about 30 to 40 minutes after a dose. This measurement generally correlates with the onset of the drug's therapeutic effect on gastrointestinal motility.


Q: What is the expected duration of therapeutic effect after taking a single dose?

Regulatory information provides the drug's elimination half-life (T1/2) as approximately 5.7 hours. This measurement is an indicator of how long the medicine stays in the body and influences the overall duration of its effects on motility after a single dose.


Q: Is Itopride hydrochloride intended for short-term symptom relief or long-term management?

The clinical studies used to establish the drug’s efficacy were generally limited to short-term periods, with treatment courses typically lasting a maximum of eight weeks. Official documents note that controlled evidence regarding the durability of effects and long-term safety beyond one year is not fully established.


Q: Are there clinical trials or studies looking at the efficacy of Itopride hydrochloride for symptoms other than functional dyspepsia?

While the drug is primarily approved for functional dyspepsia, official clinical overviews show it has been explored in studies for other conditions involving reduced gastrointestinal movement. These include research for conditions such as gastroparesis and symptoms of gastroesophageal reflux disease (GERD).

Advertisements

How should Itopride hydrochloride be stored and disposed of?

Storage and Disposal of Itopride Hydrochloride

Itopride hydrochloride tablets must be stored according to the official specifications to maintain their stability and effectiveness. The product should generally be stored below 25°C and must be protected from light and moisture. To ensure child safety, the medicine must always be kept out of the sight and reach of children.

Handling and Disposal

Tablets should be kept in the original container or blister until needed and must not be used after the expiry date. Regarding disposal, regulatory labeling strictly mandates that the medicine must not be thrown away via wastewater or household waste. All unused or expired product must be discarded in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Itopride hydrochloride found in:

A-Z Index: